Oxford Biomedica plc (LON:OXB - Get Free Report) shares crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 372.36 ($4.96) and traded as low as GBX 295 ($3.93). Oxford Biomedica shares last traded at GBX 304 ($4.05), with a volume of 483,197 shares.
Oxford Biomedica Stock Up 2.3 %
The firm's 50-day moving average price is GBX 293.14 and its 200 day moving average price is GBX 371.09. The firm has a market cap of £313.59 million, a P/E ratio of -2.19 and a beta of 1.09. The company has a debt-to-equity ratio of 166.48, a current ratio of 2.35 and a quick ratio of 1.67.
Oxford Biomedica (LON:OXB - Get Free Report) last posted its quarterly earnings results on Wednesday, April 9th. The biopharmaceutical company reported GBX (41.75) (($0.56)) earnings per share (EPS) for the quarter. Oxford Biomedica had a negative net margin of 145.98% and a negative return on equity of 202.50%. On average, equities research analysts expect that Oxford Biomedica plc will post -31.0799998 earnings per share for the current fiscal year.
Oxford Biomedica Company Profile
(
Get Free Report)
Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.
Further Reading
Before you consider Oxford Biomedica, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oxford Biomedica wasn't on the list.
While Oxford Biomedica currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
